AUTHOR=Conceição Caio César Souza , Martins Camila Marinelli , Medeiros Silva Mayck , Neto Hugo Caire de Castro Faria , Chiumello Davide , Rocco Patricia Rieken Macedo , Cruz Fernanda Ferreira , Silva Pedro Leme 

TITLE=Predicting clinical outcomes at hospital admission of patients with COVID-19 pneumonia using artificial intelligence: a secondary analysis of a randomized clinical trial

JOURNAL=Frontiers in Medicine

VOLUME=Volume 12 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1561980

DOI=10.3389/fmed.2025.1561980

ISSN=2296-858X

ABSTRACT=BackgroundPredicting clinical improvement after hospital admission in patients with COVID-19 is crucial for effective resource allocation. Machine-learning tools can help identify patients likely to show clinical improvement based on real-world data. This study used two approaches—least absolute shrinkage and selection operator (LASSO) and CombiROC—to identify predictive variables at hospital admission for detecting clinical improvement after 7 days.MethodsA secondary analysis was conducted on the modified intention-to-treat placebo group from a previous randomized clinical trial (RCT, NCT04561219) of patients with COVID-19. The analysis assessed clinical, laboratory, and blood markers at admission to predict clinical improvement, defined as a two-point increase on the World Health Organization clinical progression scale after 7 days. LASSO and CombiROC were used to select optimal predictive variables. The Youden criteria identified the best threshold for different variable combinations, which were then compared based on the highest area under the curve (AUC) and accuracy. AUCs were compared using DeLong’s algorithm.ResultsOverall, 203 patients were included in the analysis, and they were divided into two groups; clinical improvement (n = 154) and no clinical improvement (n = 49). The median age was 55 years (interquartile range, 46–66 years); 65% were male. LASSO identified three predictive variables (SaO2, hematocrit, and interleukin [IL]-13) with high sensitivity of 98% (95% confidence interval [CI], 92–100%) but low specificity of 26% (95% CI, 10–48%) for clinical improvement. CombiROC selected a broader set of variables (T cell–attracting chemokine, hemoglobin, hepatocyte growth factor, hematocrit, IL-3, PDGF-BB, RANTES, and SaO2), achieving balanced sensitivity of 82% (95% CI, 69–91%) and specificity of 74% (95% CI, 49–91%). LASSO and CombiROC showed comparable accuracy (82 and 80%, respectively) and similar area under the ROC curves (LASSO: AUC, 0.704; 95% CI, 0.571–0.837; CombiROC: AUC, 0.823; 95% CI, 0.708–0.937; p = 0.185).ConclusionFor patients hospitalized with COVID-19 pneumonia, predictive variables identified by LASSO and CombiROC analyses demonstrated similar accuracy and AUCs in predicting clinical improvement. LASSO, with fewer variables (SaO2, hematocrit, and IL-13) showed high sensitivity but low specificity, whereas CombiROC’s broader selection of variables provided balanced sensitivity and specificity for predicting clinical improvement.Clinical trial registrationBrazilian Registry of Clinical Trials (REBEC) number RBR-88bs9x and ClinicalTrials.gov number NCT04561219.